Leerink Partners Maintains Outperform on Evommune, Lowers Price Target to $22

Benzinga Newsdesk www.benzinga.com Negative 95.4%

Neg 95.4% Neu 0% Pos 0%

Leerink Partners analyst Thomas Smith maintains Evommune (NYSE:EVMN) with a Outperform and lowers the price target from $28 to $22.